Complement is an important effector pathway of innate stranded DNA antibodies was low, positive in only five immunity. In this review the role of complement in the of the 24 patients tested. pathogenesis of systemic lupus erythematosus (SLE ) is
Hereditary deficiency of C1s and C1r is rarer than described. There are important associations between that of C1q deficiency and, in the majority of cases, both inherited and acquired complement component deficiencies of both components coincide [3] [4] [5] . In such deficiencies and SLE. These have focused attention on cases C1r levels are usually absent with levels of C1s identifying the relevant physiological role of the classical below 50% of normal. As in homozygous C1q deficiency, pathway of complement activation that appears to pro-SLE occurs in the majority of these individuals (seven tect against the development of SLE. There is also of the 11 reported cases). Selective C1s deficiency, i.e. unequivocal evidence that major histocompatibility with normal C1r levels, has been reported in association complex (MHC ) genes play an important role in deterwith SLE [6 ] . In homozygous C4 deficiency, the prevalmining both disease susceptibility and phenotype in SLE ence of SLE is approximately 75% and the lupus illness and its subsets. Accordingly, the role of complement is of moderate severity [7] . genes located in the class III region (C4A, C4B and C2) Homozygous C2 deficiency is the commonest inherited in the genetic susceptibility to SLE is reviewed. The classical pathway complement deficiency with an utility of the measurement of complement levels in approximate prevalence in Western European Caucasoid monitoring disease activity and the clinical significance populations of 1:20 000. In contrast to homozygous C1q of hypocomplementaemia are discussed. Homozygous deficiency, the majority of affected individuals are probC1q deficiency is the strongest genetic susceptibility ably healthy. SLE may occur in up to 33%, although factor for SLE that has been identified in humans, but, this figure may be an overestimate due to ascertainment paradoxically, SLE causes C1q consumption and is artefact, and the severity of the illness is comparable to commonly associated with anti-C1q antibodies. The role that seen in SLE patients without homozygous compleof complement in the pathogenesis of lupus, with parment deficiency. In contrast to the classical pathway ticular emphasis on the role of C1q, is discussed in order components, homozygous C3 deficiency predisposes to to explain this paradox.
recurrent pyogenic infections and membranoproliferative glomerulonephritis (MPGN ), but SLE is rare [8] .
What do the clinical observations in individuals with
Homozygous classical pathway component homozygous classical pathway component deficiency deficiency and SLE teach us about the pathogenesis of SLE? They suggest that there is a physiological function of the classical Homozygous hereditary deficiency of each of the claspathway of complement activation that protects against sical pathway components (C1q, C1r, C1s, C4, and C2) the development of SLE. Furthermore, the hierarchy of is associated with an increased susceptibility to SLE [1] .
susceptibility and the severity of lupus, according to the Both the severity of disease and the strength of this missing classical pathway protein (C1q > C4 >> C2), association is greatest for homozygous C1q deficiency suggest that the early part of the classical pathway plays followed in turn by homozygous C4 and C2 deficiency. a key protective role against the disease. Since one of Thirty-eight of the 41 patients with homozygous C1q the major roles of the classical pathway is that of host deficiency reported to date have developed a clinical defence against infectious disease, one hypothesis is that syndrome closely similar to SLE (recently reviewed in classical pathway component deficiency predisposes to [2]). In the affected patients rash occurred in 36, glom-SLE because of impaired resistance to an infectious erulonephritis in 16, and cerebral disease in seven.
trigger. Antinuclear antibodies (ANA) were reported in 24 and There is little evidence in favour of this hypothesis. antibodies to extractable nuclear antigens in 15 of these Classical pathway complement deficiencies are not assopatients, but notably, the incidence of anti-doubleciated with an overt increase in susceptibility to viral or fungal infections. Although complement deficiency is bacterial infections, such infectious agents are not strong unusual haplotypes which are the products of recombination at some point in human history. However, candidates for the induction of SLE. Other immunodeficiencies associated with increased susceptibility to individuals bearing these recombined haplotypes are uncommon. In one study, the C4AQ*0 null allele frepyogenic bacterial infections are not associated strongly with the development of SLE.
quency was determined in Caucasoid SLE patients who were HLA-DR3 negative. Eighteen of 30 (60%) lupus Complement plays a key role in the clearance and processing of immune complexes and cellular debris and patients had extended haplotypes containing a C4 null allele compared with 22 of 60 (37%) healthy Caucasoid the evidence will be summarized that it is the role of the classical pathway that protects against the development controls (P < 0.05) [26 ] . The second approach is to analyse the HLA associof SLE.
ations of SLE in ethnic groups in which other HLA haplotypes are seen, to test the hypothesis that the C4 and C2 null alleles and SLE association with C4AQ*0 is present in different populations. A number of studies showed significant associIn view of the link between homozygous complement deficiency and SLE, it was hypothesized that partial ations between C4AQ*0 deficiency and SLE without any consistent association with HLA-DR3 [14, 15, deficiencies of C4 or C2 might also increase disease susceptibility. C4 is the product of two genes, C4A and 27-31]. For example, in African-American patients the presence of a C4AQ*0 allele confers a relative risk of C4B, and the expressed C4A and C4B proteins have slightly different functional activities. There is good 4.5 despite no association with HLA-DR3 [29] . Furthermore, in Japanese populations where the prevalevidence that C4A null alleles are important in SLE. An increased prevalence of C4A null alleles in patients ence of HLA-DR3 is extremely low, an association with C4AQ*0 was demonstrated [30] . with SLE has been found in many different populations, independent of other MHC associations. These data are However, there are also a significant number of studies which have not shown a significant association between reviewed below.
SLE and the presence of C4AQ*0 alleles. In a study of
C4 null alleles
French-Canadian and non-French-Canadian lupus patients, a significant association with C4AQ*0 could C4 is encoded by two tandemly duplicated genes, C4A and C4B, within the class III MHC region. Human C4A be demonstrated only in the non-French-Canadian group [32] . Additionally, a Spanish [33] , Greek [24] and C4B are highly polymorphic with variants including non-expressed or null alleles for which no protein prodand a recent Caucasoid study [34] failed to detect a significant association between lupus and the presence uct is identifiable (expressed as C4AQ*0 and C4BQ*0, i.e. quantity zero). A single C4 null allele may be seen of C4AQ*0 null alleles. It remains uncertain what is the relevant disease-susceptibility gene or genes within the in up to 30% of healthy Caucasoid subjects with approximately 4% having homozygous C4A deficiency and 1%
MHC.
Other candidate genes within the MHC include those homozygous C4B deficiency. Different allotypes of C4A and C4B can be detected by differences in electrophoretic encoding (i) class II gene products, controlling the repertoire of peptide presentation to T cell receptors; mobility [9] , but phenotyping is difficult in patients with active disease in whom C4 levels are usually very low
(ii) components of the antigen processing machinery, e.g. HLA-DM, -DO and proteins of the TAP (transbecause of complement activation and consumption in vivo. Following the molecular cloning of the C4 genes porters associated with antigen processing) complex; (iii) the cytokines, tumour necrosis factor-alpha and [10] , molecular typing mechanisms have enabled more accurate determination of C4 heterozygous and homozylymphotoxin and (iv) the many other proteins encoded in the MHC. Recent work has demonstrated that B cells gous deficiency states.
There is a strong association between C4AQ*0 null and resting T cells from healthy HLA-B8, -DR3 positive individuals express markedly reduced levels of Fas alleles and SLE in Caucasoid patients [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . In some studies, the association shows a gene 'dose-dependent' (CD95/APO-1) compared with cells from HLA-B8, -DR3 negative matched controls [35] . This is of direct effect: relative risk estimates for SLE in the case of homozygous C4AQ*0 deficiency have been between 9.7 relevance to SLE where, as discussed below, inefficient clearance of apoptotic cells has been implicated in the [25] Evidence for an association between C4BQ*0 alleles the major source of C4AQ*0 alleles is the commonest Caucasoid MHC haplotype: HLA-A1, -B8, CW-, -DR3, and SLE is much less strong than for C4AQ*0 alleles. Indeed the majority of studies have found no increase C4AQ*0, C4*B1, C2*C, B*fS. In view of this, it is extremely difficult to identify which is the relevant in the C4BQ deficiency of C4A and not C4B might predispose to SLE. The C4A isotype shows preferential binding There are two ways around this problem. The first is to try to identify lupus patients bearing relatively to amino groups, forming amide bonds, and binds particularly to proteins, for example in immune com-C3 nephritic factor plexes [36 ] , whilst C4B is haemolytically more active C3 nephritic factor is an IgG autoantibody directed than C4A, reflecting increased ester binding of C4B to against a neo-epitope on the fluid phase and cell-bound carbohydrates on erythrocytes. It could be hypothesized alternative pathway C3 convertase (C3iBb and C3bBb, that deficiency of C4A results in impaired processing of respectively) [53] . The binding of C3 nephritic factor to immune complexes or apoptotic cells which, as discussed the C3 convertase renders it resistant to inactivation by below, may be important in the pathogenesis of SLE.
factor H. The consequent uncontrolled alternative pathway activation results in secondary C3 deficiency. C3 C2 null alleles nephritic factor is most commonly associated with parAlthough one early study did detect an association tial lipodystrophy and MPGN type II. However, associbetween heterozygous C2 deficiency and SLE [37] , later ations between C3 nephritic factor and SLE have been studies have not confirmed this [12, 18, 38, 39] . The C2
reported [54] [55] [56] [57] [58] . In these reports the onset of SLE was null allele (C2Q*0) occurs, in the majority of cases, in between 2 and 24 yr after the onset of partial lipodysassociation with the haplotype HLA-A25, B18, CW-, trophy or nephritis. The significance of this association DR2, C4A*4, C4B*2, Bf *S [40] [41] [42] . The molecular is uncertain. It may be that common factors cause both basis of C2 deficiency associated with this extended the development of the C3 nephritic factor and SLE. haplotype consists of a 28 base pair genomic deletion However, it is rare to see C3 nephritic factor as part of that causes skipping of exon 6 during RNA splicing, the spectrum of SLE autoantibodies. Alternatively, proresulting in the generation of a premature stop codon longed C3 deficiency caused by the C3 nephritic factor, [43] . The frequency of this extended haplotype was not may predispose to the development of SLE. However, raised in a study of 248 European lupus patients [38] as discussed above, SLE is rare in homozygous C3 and none of the HLA-B18 positive lupus patients in deficiency. Furthermore, homozygous factor H defianother Caucasoid study possessed the complotype, ciency, which also results in severe C3 deficiency, has C4A*4, CAB*2, Bf *S [12] . Furthermore, the frequency only been associated with SLE in one individual who of the 28 base pair deletion associated with type I C2 was also found to have heterozygous C2 deficiency [59]. deficiency was not significantly elevated in a study of 86 Similarly, homozygous factor I deficiency, again Swedish lupus patients [39] . Therefore, it appears resulting in secondary C3 deficiency, is predominantly unlikely that partial C2 deficiency is a diseaseassociated with recurrent pyogenic infections but not susceptibility factor for the development of SLE.
SLE [8] .
Acquired deficiencies of complement proteins Complement and disease activity and SLE
The measurement of complement antigenic levels and functional activity in serum is commonly used as a SLE has also been associated with acquired complement marker of disease activity in SLE. During periods of deficiency states, particularly in patients with reduced active disease, serum complement activity is usually levels of C2 and C4 caused by the effects of inherited reduced. Typically, levels of the classical pathway com-C1 inhibitor deficiency. The presence of the autoantiponents (C1q, C2, C4) are low and, especially in patients body, C3 nephritic factor, which causes C3 consumption, with severe disease, may be accompanied by a reduction has also been associated with the presence of SLE. These in C3 levels. However, in cohorts of patients with SLE, conditions are discussed briefly below. levels of individual complement components only C1 inhibitor deficiency approximately correlate with disease activity and levels of C4 may remain low when the patient is well [60] . C1 inhibitor deficiency may be hereditary (hereditary angioedema) or acquired. Hereditary C1 inhibitor defiThis may partially be explained by the fact that the level of any serum protein is related to the rate of synthesis ciency is transmitted as an autosomal dominant trait and heterozygous individuals experience recurrent subas well as catabolism. Determinants of protein synthetic rate are not well understood and studies have shown cutaneous and submucosal swelling (recently reviewed in [44] ). In normal circumstances, this inhibitor, a serine that hypercatabolism of C3 in disease may be associated with increased or decreased synthetic rates [61] [62] [63] . This proteinase inhibitor (serpin), binds and inactivates enzymatically active C1r and C1s. Deficiency results in limits the value of the simple measurement of protein concentration in serum. uncontrolled fluid phase classical pathway activation and consequently reduced levels of both C4 and C2.
The activation or breakdown products of complement proteins have been assayed in an attempt to circumvent Following the observation that homozygous C4 and C2 deficiency predisposes to the development of SLE, it this problem. Levels of a variety of such products have been reported to correlate with disease activity more might be predicted that individuals with C1 inhibitor deficiency may have an increased likelihood of developstrongly than simple measurements of total C3 and C4 levels. Examples of assays for complement activation ing lupus and this does appear to be the case [45-52]. The incidence of SLE in individuals with hereditary C1 products in SLE include C3a [64] , iC3b [65] , C3d [66 ] and C4d [67] . Furthermore, in pregnancy, where inhibitor deficiency has been estimated at approximately 2% [46 ] . increased C3 synthesis occurs, a reduction in the ratio of total haemolytic activity (CH50) to the alternative ance of circulating immune complexes. The importance pathway activation product Ba, has been shown to be of this in the pathogenesis of SLE and the role of the most reliable complement assay in distinguishing complement in immune complex-mediated tissue active lupus from pre-eclampsia [68] . However, compleinflammation are discussed. Recent data suggesting a ment activation products are highly unstable and usually role for C1q in the clearance of apoptotic cells and have a very short half-life in plasma. At present, all possible involvement of the classical pathway in maincomplement assays are at best a very crude surrogate taining B cell tolerance are summarized. marker of disease activity in SLE.
Role of complement in immune complex processing and It should also be appreciated that other factors, immune complex-mediated tissue inflammation independent of disease activity, may affect complement levels in lupus patients. The most important are a series
The role of complement in the processing of immune of autoantibodies to complement proteins which include:
complexes has been reviewed in detail recently and will anti-C1q autoantibodies [69] , anti-C1 inhibitor antionly be summarized here [81] . The classical pathway of bodies [70, 71] , classical pathway nephritic factor (an complement activation inhibits the formation of precipitautoantibody to the classical pathway C3 convertase, ating immune complexes in plasma [82] and alternative C4b2a) [72] and C3 nephritic factor [53] .
pathway activation is able to solubilize immune comIt has been suggested that the measurement of compleplexes that have formed or are deposited in tissues. In ment activity may identify patients at risk of developing vivo clearance studies, following intravenous injection lupus nephritis. An early study demonstrated that of complement-fixing immune complexes, have demonnormal C3 levels were rarely detected in the presence of strated that circulating immune complexes bind to CR1 active nephritis [60] . More recently, the presence of (CD35, immune adherence receptor, C3b/C4b receptor) anti-C1q antibodies in SLE has been found to correlate present on the surface of erythrocytes [83] . The complestrongly with the presence of proliferative nephritis with ment ligands for CR1 include C3b, C4b and iC3b, and a positive predictive value of 50-58% and a negative recent data suggest that C1q may also bind to CR1 predictive value of 96.5-100% [73, 74] . Anti-C1q anti- [84] . C3b covalently incorporated into immune complex bodies are IgG autoantibodies that are directed against lattices interferes with the interaction between antibody neo-epitopes on the collagen-like region of the C1q and antigen, limiting the formation of large complexes. molecule [69] . These antibodies, found in 34-59% of In addition, incorporation of C3b in circulating immune lupus patients [75] , show a significant inverse correlation complexes, via its interaction with erythrocyte CR1, with levels of C1q, C3 and C4 [73, 76 ] . Increases in allows immune complexes to be transported to the fixed anti-C1q antibody titres have been shown to precede cells of the mononuclear phagocytic system, predomirenal involvement in SLE [76 ] and, in contrast to nantly in the liver and spleen. Therefore, chronic hypoincreases in anti-DNA antibody titres, appear specificcomplementaemia would be expected to be associated ally to increase prior to renal relapse [77] . Furthermore, with defective clearance of circulating complement-fixing these antibodies have been recovered from renal biopsies immune complexes. This has been tested experimentally. of lupus patients with proliferative nephritis in higher Two studies found that hypocomplementaemic patients concentrations than that of serum [78] , supporting the showed reduced splenic but enhanced hepatic uptake of hypothesis that they play a direct role in the pathogenesis injected radio-labelled circulating immune complexes of the nephritis. [85, 86 ] . Despite enhanced hepatic uptake, immune complexes were retained in the liver inefficiently and Infection and hypocomplementaemia in SLE slowly released back into the circulation. A striking There is one extremely important clinical association of demonstration of the role of complement in the splenic hypocomplementaemia in SLE. Patients with chronic uptake of immune complexes was shown in a C2-hypocomplementaemia are at particular risk of developdeficient individual in whom splenic uptake, initially ing serious infection with encapsulated organisms such absent, was restored following administration of fresh as Streptococcus pneumoniae and Neisseria meningitidis.
frozen plasma [86 ] . The observation that hypocompleThese patients can be considered to be 'functionally mentaemia is associated with defective clearance of asplenic' because the hypocomplementaemia, in addition immune complexes has led to the hypothesis that comto causing defective opsonization and local phagocytplement deficiency, as a consequence of this defective osis, also results in reduced splenic clearance of these processing, results in increased tissue deposition of organisms [79] . There is a strong case that such patients, immune complexes. Subsequent inflammation could analogous to standard post-splenectomy prophylaxis, then result in exposure of autoantigens, driving an receive prophylactic penicillin therapy and be considered autoantibody response and the development of autofor both pneumococcal and meningococcal vaccination immunity. [80] .
However, the presence of immune complexes in tissues with associated complement activation does not always
The role of complement in the pathogenesis result in tissue inflammation. It has been established of SLE that immune complexes, C1q and C3 may be present in tissues despite the absence of clinical and histological One of the important physiological functions of the classical pathway of complement activation is the clearinflammation. This is clearly illustrated in the skin of patients with SLE where dermal-epidermal deposits of and small nuclear ribonucleoproteins) and have phosphatidylserine present on their surface [98, 99] . In immunoglobulins, C1q and C3 may be found in normal as well as inflamed lesional skin, the so-called 'lupus addition to being concentrated in the surface blebs, these autoantigens may also be altered by apoptoticband' test [87] . Recently, comparative studies in complement-deficient and Fc receptor-deficient mice, have highspecific proteases allowing the exposure of potentially immunogenic cryptic epitopes [100] [101] [102] . Furthermore, lighted the important role of Fc receptors (cellular receptors for IgG) in the development of immune comnormal mice injected intravenously with syngeneic apoptotic thymocytes, have been shown to develop ANA, plex-mediated inflammation [88] . For example, Fc-c chain-deficient NZB/NZW mice are protected from anti-single-stranded DNA and anti-cardiolipin antibodies [103] . developing severe nephritis despite the presence of immune complexes in the kidney [89] . Furthermore, It may also be that proteins that bind to apoptotic cells may become part of complexes of autoantigens. mice deficient in the inhibitory Fc receptor, Fc-cRII, develop severe immune complex alveolitis using doses This could explain the finding that a number of proteins, such as b2-glycoprotein I and annexin V, that bind to of immune complexes that do not elicit inflammation in wild-type controls [90] . In a murine model of the reverse phosphatidylserine, a negatively charged phospholipid exposed on the outer lamella of apoptotic cell mempassive cutaneous Arthus reaction, C3-/-and C4-/-mice developed inflammatory responses comparable branes, elicit an autoantibody response in many patients with SLE. Another such binding protein to apoptotic with those seen in wild-type control mice, whereas the response of Fc-c chain-deficient mice was significantly cells may be C1q, which could explain the high prevalence of autoantibodies to C1q in SLE, although it is reduced [91] . This would suggest that inflammation in this model is independent of complement activation.
not yet known to what moiety on apoptotic cells C1q binds. Moreover, it has recently been shown that the spontaneous glomerulonephritis observed in C1qa-/-mice is Further evidence supporting a role for C1q in the clearance mechanisms of apoptotic cells follows the independent of C3 activation [92] .
However, in some experimental models there are clear observation that C1qa-/-mice, on a mixed genetic background (129/Ola × C57BL/6), develop proliferatdata showing a role for complement in the induction of inflammatory injury. For example. mice deficient in the ive glomerulonephritis characterized by the presence of large numbers of glomerular apoptotic bodies [104] . C5a anaphylatoxin receptor show marked reduction in inflammation in both peritoneal and cutaneous reverse
The finding of excess glomerular apoptotic bodies in non-diseased C1qa-/-kidneys compared with nonpassive Arthus reactions [93] . Moreover, both complement activation and activation of Fc-cRI on peritoneal diseased genetically matched controls, suggested that this was the primary defect. The C1qa-/-male mice on macrophages were required to initiate inflammation in a murine model of immune complex peritonitis [94] .
a mixed genetic background also developed significantly higher titres of ANA at the age of 8 months compared These findings, showing that the mechanism of induction of inflammation by immune complexes may with controls (54 vs 33%). Although many aspects of this hypothesis remain be complement-independent or complement-dependent, should not be interpreted as contradictory. They serve untested, it could provide a unifying explanation for the paradoxical finding that homozygous C1q deficiency to illustrate the complexity of mechanisms of inflammation in disease mediated by immune complexes. 
